Morand Réjane, Bouitbir Jamal, Felser Andrea, Hench Jürgen, Handschin Christoph, Frank Stephan, Krähenbühl Stephan
Clinical Pharmacology and Toxicology, University Hospital Basel, 4031, Basel, Switzerland.
Eur J Nutr. 2014 Sep;53(6):1313-25. doi: 10.1007/s00394-013-0631-6. Epub 2013 Dec 11.
Pharmacokinetics and effects on skeletal muscle and physical performance of oral acetylcarnitine and propionylcarnitine are not well characterized. We therefore investigated the influence of oral acetylcarnitine, propionylcarnitine, and carnitine on body carnitine homeostasis, energy metabolism, and physical performance in mice and compared the findings to non-supplemented control animals.
Mice were supplemented orally with 2 mmol/kg/day carnitine, acetylcarnitine, or propionylcarnitine for 4 weeks and studied either at rest or after exhaustive exercise.
In the supplemented groups, total plasma and urine carnitine concentrations were significantly higher than in the control group receiving no carnitine, whereas the skeletal muscle carnitine content remained unchanged. The supplemented acylcarnitines were hydrolyzed in intestine and liver and reached the systemic circulation as carnitine. Bioavailability of carnitine and acylcarnitines, determined as the urinary excretion of total carnitine, was in the range of 19 %. Skeletal muscle morphology, including fiber-type composition, was not affected, and oxygen consumption by soleus or gastrocnemius fibers was not different between the groups. Supplementation with carnitine or acylcarnitines had no significant impact on the running capacity, but was associated with lower plasma lactate levels and a higher glycogen content in white skeletal muscle after exhaustive exercise.
Oral supplementation of carnitine, acetylcarnitine, or propionylcarnitine in mice is associated with increased plasma and urine total carnitine concentrations, but does not affect the skeletal muscle carnitine content. Despite better preservation of skeletal muscle glycogen and lower plasma lactate levels, physical performance was not improved by carnitine or acylcarnitine supplementation.
口服乙酰肉碱和丙酰肉碱的药代动力学及其对骨骼肌和身体机能的影响尚未得到充分阐明。因此,我们研究了口服乙酰肉碱、丙酰肉碱和肉碱对小鼠体内肉碱稳态、能量代谢及身体机能的影响,并将研究结果与未补充肉碱的对照动物进行比较。
给小鼠口服补充2 mmol/kg/天的肉碱、乙酰肉碱或丙酰肉碱,持续4周,分别在静息状态或力竭运动后进行研究。
在补充组中,血浆和尿液中总肉碱浓度显著高于未补充肉碱的对照组,而骨骼肌中的肉碱含量保持不变。补充的酰基肉碱在肠道和肝脏中被水解,并以肉碱的形式进入体循环。以总肉碱的尿排泄量测定的肉碱和酰基肉碱的生物利用度在19%的范围内。骨骼肌形态,包括纤维类型组成,未受影响,比目鱼肌或腓肠肌纤维的耗氧量在各组之间无差异。补充肉碱或酰基肉碱对跑步能力没有显著影响,但与力竭运动后血浆乳酸水平降低和白色骨骼肌糖原含量升高有关。
小鼠口服补充肉碱、乙酰肉碱或丙酰肉碱会使血浆和尿液中总肉碱浓度升高,但不影响骨骼肌中的肉碱含量。尽管补充肉碱或酰基肉碱能更好地保存骨骼肌糖原并降低血浆乳酸水平,但身体机能并未得到改善。